ZA200410229B - Administration of therapeutic viruses - Google Patents

Administration of therapeutic viruses

Info

Publication number
ZA200410229B
ZA200410229B ZA200410229A ZA200410229A ZA200410229B ZA 200410229 B ZA200410229 B ZA 200410229B ZA 200410229 A ZA200410229 A ZA 200410229A ZA 200410229 A ZA200410229 A ZA 200410229A ZA 200410229 B ZA200410229 B ZA 200410229B
Authority
ZA
South Africa
Prior art keywords
administration
therapeutic viruses
viruses
therapeutic
Prior art date
Application number
ZA200410229A
Other languages
English (en)
Inventor
Robert M Lorence
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Publication of ZA200410229B publication Critical patent/ZA200410229B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200410229A 2002-06-21 2004-12-20 Administration of therapeutic viruses ZA200410229B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39063202P 2002-06-21 2002-06-21

Publications (1)

Publication Number Publication Date
ZA200410229B true ZA200410229B (en) 2006-07-26

Family

ID=30000590

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200410229A ZA200410229B (en) 2002-06-21 2004-12-20 Administration of therapeutic viruses

Country Status (11)

Country Link
US (2) US20050220818A1 (fr)
EP (2) EP2266601A1 (fr)
JP (1) JP2006511450A (fr)
AU (1) AU2003243307B2 (fr)
CA (1) CA2489523A1 (fr)
IL (1) IL165860A0 (fr)
MX (1) MXPA04012881A (fr)
NZ (1) NZ537255A (fr)
RU (1) RU2314830C2 (fr)
WO (1) WO2004000209A2 (fr)
ZA (1) ZA200410229B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207149A1 (en) 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
RU2379055C1 (ru) * 2008-04-30 2010-01-20 Виктор Владимирович Кешелава Способ лечения онкологических заболеваний
ES2380289T3 (es) 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
WO2013052915A2 (fr) 2011-10-05 2013-04-11 Genelux Corporation Procédé de détection de la réplication ou colonisation d'un produit thérapeutique biologique
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (fr) 2012-04-20 2013-10-24 Genelux Corporation Méthodes d'imagerie pour virothérapie oncolytique
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
WO2017181152A2 (fr) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants de cd80 et leurs utilisations
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (fr) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants de cd112 et utilisations associées
WO2018022946A1 (fr) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants de cd155 et leurs utilisations
WO2018075978A1 (fr) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Protéines immunomodulatrices sécrétables de type variant et thérapie cellulaire utilisant des cellules obtenues par génie génétique
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
EP3596116B1 (fr) 2017-03-16 2023-09-06 Alpine Immune Sciences, Inc. Protéines immunomodulatrices de variants de pd-l1 et utilisations associées
SG11201907769XA (en) 2017-03-16 2019-09-27 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
KR20190141146A (ko) 2017-03-16 2019-12-23 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l2 변이체 면역조절 단백질 및 그의 용도
BR112020007542A2 (pt) 2017-10-18 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
EA202000353A1 (ru) 2018-06-04 2022-01-14 Калиди Биотерапьютикс, Инк. Основанные на клетках носители для потенциализации вирусной терапии
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
WO2019241758A1 (fr) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Protéines immunomodulatrices de variants de pd-l1 et utilisations associées
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3116192C (fr) 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. Systemes ameliores pour therapie virale oncolytique a mediation cellulaire
EP3884041A2 (fr) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Procédés d'amplification d'un sous-ensemble de cellules tueuses naturelles (nk) et compositions et procédés associés
CA3120868A1 (fr) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Proteines immunomodulatrices a variants cd86 et leurs utilisations
JP2022524951A (ja) 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
AU2021258194A1 (en) 2020-04-22 2022-11-24 Indapta Therapeutics, Inc. Natural killer (NK) cell compositions and methods for generating same
WO2021258008A1 (fr) * 2020-06-19 2021-12-23 Immunacor Llc Compositions et méthodes de traitement et de prévention d'infection virale
WO2022147480A1 (fr) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Virus oncolytique codant pour la sialidase et agent de ciblage de cellule immunitaire multispécifique

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
CA2161671A1 (fr) * 1993-04-30 1994-11-10 Robert M. Lorence Methodes pour le traitement et la detection de cancers a l'aide de virus
AU687117B2 (en) * 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
EP0848956A1 (fr) * 1996-12-17 1998-06-24 Dimminaco Ag/Sa/Ltd. In ovo vaccination contre la maladie de Newcastle
CN101618049A (zh) * 1997-10-09 2010-01-06 威尔斯塔特生物公司 使用病毒来治疗赘生物
US7470426B1 (en) * 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
IL145899A0 (en) 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
US20050074901A1 (en) * 2002-02-13 2005-04-07 John Castracane Methods and assays for detecting and quantifying the human p53 inducible gene protein
CA2502890A1 (fr) * 2002-11-05 2004-05-27 Wellstat Biologics Corporation Traitement des tumeurs carcinoides par des virus therapeutiques

Also Published As

Publication number Publication date
AU2003243307B2 (en) 2010-04-01
RU2314830C2 (ru) 2008-01-20
AU2003243307A1 (en) 2004-01-06
EP1539230A4 (fr) 2007-10-31
WO2004000209A3 (fr) 2005-03-03
US20090180993A1 (en) 2009-07-16
MXPA04012881A (es) 2005-07-05
CA2489523A1 (fr) 2003-12-31
IL165860A0 (en) 2006-01-15
WO2004000209A2 (fr) 2003-12-31
EP1539230A2 (fr) 2005-06-15
NZ537255A (en) 2009-04-30
EP2266601A1 (fr) 2010-12-29
JP2006511450A (ja) 2006-04-06
US20050220818A1 (en) 2005-10-06
RU2005101351A (ru) 2005-08-10

Similar Documents

Publication Publication Date Title
IL165860A0 (en) Administration of therapeutic viruses
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
IL169338A0 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
IL163725A0 (en) Administration of agents for the treatment of inflammation
AU2003224725A8 (en) Hiv therapeutic
EP1487411A4 (fr) Formulations therapeutiques soutenues respirables
AU2003279911A8 (en) Therapeutic formulations
TWI319400B (en) Piperazinylacylpiperidine derivatives, their preparation and their therapeutic application
IL172733A0 (en) Diphenylpyridine derivatives, preparation and therapeutic application thereof
AU2003294318A8 (en) Therapeutic bioconjugates
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
GB0223367D0 (en) Therapeutic treatment
PT1525193E (pt) Derivados do acilaminotiazole e sua utilização como inibidores de beta amilóide
GB0202900D0 (en) Novel formulations of drugs
IL166337A0 (en) Oral administration of calctionin
GB0223854D0 (en) Therapeutic treatment
AU2003296385A8 (en) Therapeutic single dose gas administration system
GB0210464D0 (en) Therapeutic treatment
IL165612A0 (en) Novel arylimidazole derivatives preparation and therapeutic uses thereof
GB0210741D0 (en) Methods of therapy
PL375309A1 (en) Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
HK1075830A (en) Administration of therapeutic viruses
GB0213383D0 (en) Therapeutic conditions
GB0208324D0 (en) Administration of beneficial substances